Aristeia Capital’s EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share EQHA.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-282,599
Closed -$24K 692
2022
Q3
$24K Hold
282,599
﹤0.01% 559
2022
Q2
$24K Hold
282,599
﹤0.01% 614
2022
Q1
$89K Buy
+282,599
New +$103K ﹤0.01% 569

Other funds holding EQHA.WS

Aristeia Capital's EQHA.WS Position: Q4 2022 in Review

Aristeia Capital sold out of EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share (EQHA.WS) in Q4 2022, closing a stake of 282,599 shares — an estimated $24K sold.

Aristeia Capital first reported a position in EQHA.WS in Q1 2022 and held it in 3 quarters. The position peaked at $89K in Q1 2022. 1 fund tracked by Wall St. Rank holds EQHA.WS as of Q4 2022.

  • Aristeia Capital reported no remaining EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share position as of Q4 2022 after selling out during the quarter.
  • Aristeia Capital sold 282,599 EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share shares in Q4 2022, an estimated $24K.
  • Aristeia Capital first reported a position in EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share in Q1 2022 and held it in 3 quarters.
  • Aristeia Capital's EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share position peaked at $89K in Q1 2022.
  • 1 fund tracked by Wall St. Rank held EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share as of Q4 2022.

Based on Aristeia Capital's 13F filing for Q4 2022, filed 14 Feb 2023.